Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report)’s stock price traded down 2.7% on Friday . The stock traded as low as $0.33 and last traded at $0.36. 2,808 shares were traded during trading, a decline of 99% from the average session volume of 281,870 shares. The stock had previously closed at $0.37.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “neutral” rating on shares of Panbela Therapeutics in a research note on Thursday, August 15th.
View Our Latest Stock Analysis on PBLA
Panbela Therapeutics Stock Performance
Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.60. On average, equities research analysts expect that Panbela Therapeutics, Inc. will post -6.76 earnings per share for the current fiscal year.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Further Reading
- Five stocks we like better than Panbela Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- What Are Dividend Challengers?
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Compound Interest and Why It Matters When Investing
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.